media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Subsidiary Signs Exclusive Licensing Agreement for GenSci098 Injection Project

According to the announcement, the company’s subsidiary, Shanghai Saizeng Medical Technology Co., Ltd. (hereinafter referred to as “Saizeng Medical”), recently signed an exclusive licensing agreement with Yarrow Bioscience, Inc. for the GenSci098 injection project. Under the agreement, Saizeng Medical expects to receive an upfront payment of US$120 million and near-term development milestone payments (including a non-refundable and non-deductible upfront payment of US$70 million and subsequent near-term development milestone payments of US$50 million), and will be eligible for milestone payments related to specific research, regulatory, and commercialization. Saizeng Medical will be entitled to receive up to US$1.365 billion in milestone payments for this exclusive license, and will also be entitled to royalties exceeding 10% of net sales after the product’s launch. https://finance.eastmoney.com/a/202512153591987252.html
- Source: drugdu
- 39
- December 17, 2025
Kangfeng Biotechnology’s Anti-Gastroesophageal Reflux System Receives Approval from the Drug Administration

On December 16, Kangfeng Bio-B (06922) issued an announcement stating that its anti-gastroesophageal reflux system received approval from the National Medical Products Administration on December 15, 2025. The anti-gastroesophageal reflux system is a surgical instrument independently developed by the company. It consists of an implantable anti-gastroesophageal reflux device and an esophageal measuring tool. The working principle is to fix the device in the functional area of the lower esophageal sphincter outside the esophagus, and use the magnetic attraction generated by the magnetic beads in the device to enhance the tension of the lower esophageal sphincter, thereby restoring its anti-reflux function and treating gastroesophageal reflux disease. https://finance.eastmoney.com/a/202512163593180489.html
- Source: drugdu
- 40
- December 17, 2025
Cell Metabolism | Efficacy of Akkermansia muciniphila Supplementation in Overweight/Obese Patients with Type 2 Diabetes

On January 28, 2025, Cell Metabolism (IF=27.7) published online a research report titled“Supplementation with Akkermansia muciniphila in Overweight/Obese Patients with Type 2 Diabetes: Efficacy Depends on Its Baseline Abundance in the Gut.” This study employed a combined approach of multicenter clinical intervention research and animal experiments to reveal for the first time that the efficacy of Akkermansia muciniphila (abbreviated as AKK) in clinical weight loss and glucose lowering largely depends on the individual’s baseline abundance of AKK bacteria in the gut. The study found that supplementation with AKK demonstrated significant metabolic improvement only in patients with low baseline AKK abundance in their intestines. This breakthrough discovery moves beyond the “one-size-fits-all” model of probiotic supplementation, proposing a “supplement only if deficient” philosophy for precise probiotic use. It provides a key example of precision probiotic intervention based on individual gut microbiota ecology and is expected to advance the development of personalized probiotic ...
- Source: drugdu
- 35
- December 17, 2025
Major Breakthrough! China’s First Injectable Silk Fibroin Gel Enters Clinical Trials

On December 15, 2025, the clinical trial initiation meeting for the injectable silk fibroin gel, led by Director Zhao Hongyi, Chairman of the Plastic and Aesthetic Branch of the China Medical Device Industry Association, was launched at Beijing Hospital of Traditional Chinese Medicine affiliated with Capital Medical University. This study, initiated by Venusilk, is China’s first prospective, multicenter, randomized, positive parallel-controlled, evaluator-blinded, non-inferiority clinical trial for an injectable silk fibroin gel. It is primarily designed to validate the safety and efficacy of the filler injectable silk fibroin gel in correcting dynamic forehead wrinkles (forehead lines). The trial will be conducted simultaneously across five clinical trial centers nationwide. (Injection Silk Fibroin Gel Clinical Trial Initiation Meeting, On-site Photos) The initiation of this trial marks the entry of China’s first injectable silk fibroin gel into a new phase, bringing it closer to regulatory approval and future clinical availability, thereby accelerating patient access ...
- Source: drugdu
- 35
- December 17, 2025
Can AOC become the “next stop” for oligonucleotide therapy?

In recent years, the nucleic acid industry has developed rapidly, with many small nucleic acid drugs successfully approved for marketing, bringing revolutionary breakthroughs in the treatment of rare diseases, infectious diseases and other fields, and propelling gene therapy into a golden age of rapid development. However, traditional small nucleic acid drugs still face many bottlenecks in the delivery process. For example, therapies represented by GalNAc delivery technology are mostly limited to liver targeting, making it difficult to achieve effective delivery to extrahepatic tissues such as muscles and the central nervous system. They also have problems such as short half-life and high off-target toxicity, which greatly limit their clinical application. A few years ago, the emergence of AOC (antibody-oligonucleotide conjugate) initially solved the delivery problem that had previously hindered the development of small nucleic acid drugs. Its unique structural design and technological advantages have also made it the core direction of ...
- Source: drugdu
- 36
- December 17, 2025
A global first! Two domestically developed innovative medical devices have been approved for market launch

Recently, the National Medical Products Administration approved the registration applications of two innovative products, namely: Disposable sterile urinary catheters from Taizhou Dubomai Medical Device Co., Ltd.; Transcatheter aortic valve system from Peijia Medical Technology (Suzhou) Co., Ltd. Among them, Peijia Medical Technology (Suzhou) Co., Ltd.’s transcatheter aortic valve system is the first domestically approved integrated positioning key transfemoral approach aortic valve regurgitation (AR) dedicated interventional treatment device. Image source: Peijia Medical’s official WeChat account The product’s aortic valve positioning key design is expected to enable precise valve positioning and anchoring; the large mesh design at the outflow end is expected to reduce the difficulty of subsequent coronary re-intervention in patients with low coronary artery disease; and the high-density diamond-shaped mesh design at the inflow end is expected to provide good occlusion. Furthermore, the adjustable bend and rotatable design of the delivery system is expected to improve the accuracy of valve ...
- Source: drugdu
- 34
- December 17, 2025
MWN109 (including injection and oral tablets) is a drug independently developed by the company

Securities Daily Online News: On December 16, Lepu Medical stated in response to investor inquiries on its interactive platform that MWN109 (including injection and oral tablets) is a drug independently developed by the company. The company holds its global intellectual property rights and has already applied for patent protection for key aspects, such as the core compound structure. Furthermore, the drug has passed the Freedom to Operate (FTO) analysis. https://finance.eastmoney.com/a/202512163593263249.html
- Source: drugdu
- 35
- December 17, 2025
Announcement on Obtaining the “Approval Letter for Drug Clinical Trial” of an Innovative Drug

Securities Daily Online News: On the evening of December 16, Haisco Pharmaceutical Group issued an announcement stating that its subsidiary, Shanghai Haisco Shennuo Pharmaceutical Technology Co., Ltd., recently received the “Approval Letter for Drug Clinical Trial” issued by the National Medical Products Administration (NMPA). Following review, the Clinical Trial Applications (CTA) for HSK45019 Tablets, HSK50042 Tablets, HSK55718 for Injection, and HSK36357 Capsules, which were accepted in October 2025, have met the relevant requirements for drug registration. Approval has been granted to proceed with clinical trials. https://finance.eastmoney.com/a/202512163593304242.html
- Source: drugdu
- 34
- December 17, 2025
Urine-based microRNA clock predicts biological aging without a blood test

In a recent study published in the journal npj Aging, researchers developed a urinary microRNA (miRNA) aging clock that predicts chronological age from urinary miRNA profiles, with deviations used as an indirect indicator of biological age acceleration rather than a direct measurement of biological age. Aging remains the primary driver of chronic diseases, yet reliable, non-invasive biomarkers of biological age are limited. Aging clocks are biomarker-based models that estimate biological age from age-responsive characteristics, and deviations from chronological age reflect the pace of aging. These clocks are associated with morbidity and mortality risk and are used to stratify health risk and assess interventions. miRNAs have been linked to age-related disorders and aging. Aging clocks based on miRNAs in skin, blood, and plasma have been developed. Beyond skin, solid tissues exhibit reproducible age-related miRNA shifts. While tissue or blood sampling requires invasive procedures at medical facilities, urine represents a non-invasive, scalable, ...
- Source: drugdu
- 34
- December 17, 2025
Salutogenic microbes offer new pathways to better health

Viruses and bacteria get a bad rap around the world but now Flinders University experts are identifying the positive ‘upside’ of powerful benefits that microbes have on human health. Flinders microbial ecologist Dr Jake Robinson and colleagues have presented a timely reminder of these ‘invisible friends’ in a new article published in Microbial Biotechnology, underlining the benefits of moving away from a threat-centred view of microbes and biogenic compounds. The article introduces the ‘Database of Salutogenic Potential’, a world-first prototype open-access repository that catalogues microbes and natural compounds linked to positive health outcomes. “Emerging evidence shows that exposure to diverse environmental microbiomes and natural biochemical products also promotes health and resilience,” says Dr Robinson. “Rather than viewing biodiversity as something to be eliminated, contemporary approaches recognise the vital role of diverse ecosystems in creating salutogenic, or health-promoting, environments. “By consolidating this data, we aim to rebalance the story of microbes ...
- Source: drugdu
- 39
- December 17, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.